Ikena Oncology Discontinues IK-930 Program And Cuts Workforce, Analyst Calls It 'Disappointing'
Ikena Oncology Discontinues IK-930 Program And Cuts Workforce, Analyst Calls It 'Disappointing'
On Tuesday, Ikena Oncology Inc (NASDAQ:IKNA) discontinued the clinical IK-930 program, the company's TEAD1- selective Hippo pathway inhibitor, and continued clinical development of IK-595, a novel MEK-RAF molecular glue.
在週二，艾克納腫瘤公司（納斯達克:IKNA）取消了臨床IK-930項目，其中包括公司的TEAD1選擇性河馬通路抑制劑，並繼續IK-595的臨床開發，這是一種新型MEK-RAF分子膠粘劑。
Concurrently, Ikena is evaluating strategic options for the company and its development pipeline.
同時，艾克納正在評估公司及其開發管道的戰略選擇。
The company said that based on a review of clinical data to date, available resources, and strategic priorities, the company decided to discontinue the development of IK-930.
該公司表示，在對迄今爲止的臨床數據、可用資源和戰略重點進行審查後，決定停止IK-930的開發。
The IK-930 Phase 1 program will begin winding down activities; treatment will continue for enrolled patients who have derived benefits.
IK-930第一階段計劃將開始減少活動；已獲益的註冊患者將繼續接受治療。
The company will seek strategic options for the program, including potential partners for developing IK-930 in combination with other targeted agents.
該公司將尋求計劃的戰略選擇，包括與其他靶向藥物合併開發IK-930的潛在合作伙伴。
In November 2023, Ikena shared initial data from twenty-six patients treated in the ongoing dose escalation portion of the Phase 1 trial of IK-930.
2023年11月，艾克納分享了26名接受IK-930一期劑量遞增試驗的患者的初步數據。
In connection with the discontinuation of IK-930 development, the company is executing a workforce reduction of approximately 53%
由於IK-930開發的中斷，該公司正在執行約53%的人員裁員。
Ikena reported $157 million in cash, cash equivalents, and marketable securities as of March 31, 2024.
截至2024年3月31日，艾克納報告持有現金、現金等價物和市場證券共計1.57億美元。
William Blair writes, "The discontinuation of IK-930 is clearly a disappointment, as it removes the potential for a meaningful clinical catalyst later this year with the updated formulation following a disappointing initial clinical readout in the fall of 2023."
威廉·布萊爾（William Blair）寫道：“IK-930的中止顯然令人失望，因爲它消除了今年晚些時候更新的配方後的重要臨床動力事件的潛力，這是在2023年秋季首次臨床閱讀不佳後發生的。”
The analyst adds, "We believe clear single-agent activity with IK-595 will be needed to generate significant interest and share appreciation beyond the cash balance." William Blair maintains an Outperform rating.
分析師補充說：“我們相信，需要通過IK-595的清晰單一藥物活性來產生除現金結餘外的重大興趣和股票升值。”威廉·布萊爾維持Outperform評級。
Management expressed enthusiasm about IK-595's profile and its potential for a simpler development path in significantly larger market opportunities.
管理層對IK-595的概況及其在更大市場機會上擁有更簡單的開發路徑的潛力表示熱情。
Wedbush writes, "While IK-595 showed encouraging preclinical activity against multiple xenograft models of cancers with different RAS/MAPK alterations, we are moving to the sidelines regarding shares until management discloses more data and development plans for the asset, given the competition in the space."
Wedbush寫道：“儘管IK-595對多種具有不同RAS / MAPK改變的癌症移植模型顯示出令人鼓舞的體外活性，但我們正對股票持觀望態度，直到管理層披露更多的數據和資產的開發計劃，因爲該領域競爭激烈。”
Wedbush has downgraded the stock to Neutral from Outperform, cutting the price target to $2 from $8.
Wedbush將股票評級從Outperform降至Neutral，將價格目標下調至2美元，而原來的價格目標爲8美元。
Price Action: IKNA shares are up 23.30% at $1.64 at the last check on Wednesday.
價格走勢：截至週三的最後一次檢查，IKNA股價上漲23.30%，爲1.64美元。